Dosing of ritonavir-boosted darunavir for treatment of HIV in pregnancy
Authors:
Open Access
- 11 February 2026
- journal article
- Published by Wolters Kluwer Health in AIDS
- Vol. 40 (6) , 831-839
Abstract
Objective: To assess the effectiveness of once- and twice-daily ritonavir-boosted darunavir (DRV/r)-containing regimens for treating HIV in pregnancy to inform the 2025 World Health Organization antiretroviral treatment guidelines update. Design: Analysis of pooled data from two observational study networks with sites in Romania, Switzerland, and the United Kingdom. Methods: Pregnancies resulting in a live birth or stillbirth in women receiving 800/100 mg DRV/r once-daily or 600/100 mg twice-daily during pregnancy were included. The primary outcome was viral suppression (<50 copies/ml) near delivery (from 28 days prior to 7 days after delivery). Results: Among 162 women on once-daily DRV/r, 95% were virally suppressed near delivery, with no difference between those on DRV/r from conception (95%, 113/119) and those who started on or switched to DRV/r during pregnancy (95%, 41/43). Among 27 women on twice-daily DRV/r, 78% were virally suppressed near delivery. Most women remained on the same DRV/r regimen until delivery, and there were no vertical transmissions. Darunavir drug concentrations for the limited number of pregnancies with data available fell within the expected ranges. Conclusions: This analysis provides some reassurance that once-daily DRV/r can be used successfully in pregnancy. However, given the possibility of reduced drug levels in pregnancy with once-daily dosing, viral load monitoring during pregnancy remains essential. Surveillance of pregnancies in women receiving once-daily DRV/r is needed to further support the use of this dosing during pregnancy.Keywords
This publication has 21 references indexed in Scilit:
- Modern antiretroviral regimens in pregnant women: virologic outcomes and durabilityAIDS, 2023
- Dolutegravir in Pregnancy as Compared with Current HIV Regimens in the United StatesNew England Journal of Medicine, 2022
- Pharmacokinetics of darunavir and cobicistat in pregnant and postpartum women with HIVAIDS, 2021
- Darunavir Pharmacokinetics With an Increased Dose During PregnancyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2020
- Association of maternal antiretroviral use with microcephaly in children who are HIV-exposed but uninfected (SMARTT): a prospective cohort studyThe Lancet HIV, 2020
- Evaluating darunavir/ritonavir dosing regimens for HIV-positive pregnant women using semi-mechanistic pharmacokinetic modellingJournal of Antimicrobial Chemotherapy, 2019
- Efficacy and safety of boosted darunavir-based antiretroviral therapy in HIV-1-positive patients: results from a meta-analysis of clinical trialsScientific Reports, 2018
- Pharmacokinetics of Once Versus Twice Daily Darunavir in Pregnant HIV-Infected WomenJAIDS Journal of Acquired Immune Deficiency Syndromes, 2015
- Differential Body Composition Effects of Protease Inhibitors Recommended for Initial Treatment of HIV Infection: A Randomized Clinical TrialClinical Infectious Diseases, 2014
- Pharmacokinetics of total and unbound darunavir in HIV-1-infected pregnant women*Journal of Antimicrobial Chemotherapy, 2014